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Introduction
Broadly neutralizing anti-HIV antibody responses are generated
by approximately 15% of those infected with HIV-1 [1–4] and
monoclonal antibodies (MAbs) with broad and potent anti-HIV
neutralizing activities have been isolated from chronically HIV-1-
infected subjects [5–11]. The structures and locations on the viral
envelope glycoprotein (Env; the sole target of anti-HIV neutral-
izing antibodies) of the epitopes recognized by many broadly
neutralizing MAbs have been characterized [6,7,12–15] and
recombinant forms of Env have been engineered to express the
epitopes of broadly neutralizing MAbs. Such Env proteins have
been shown to be recognized by known broadly neutralizing
MAbs and to adsorb the broadly neutralizing activities of HIV+
sera [2,3,16–22]; indications that these proteins effectively present
the epitopes targeted by bNAbs generated during HIV-infection.
Despite however, the presence of epitopes recognized by bNAbs
on such Env proteins, these constructs when used as immunogens
fail to elicit similar types of broadly neutralizing antibody
responses [16,23–35]. To overcome this major obstacle in HIV
vaccine-development, diverse approaches were evaluated over the
past two decades, (reviewed in [36]). So far however, these
approaches were met with very limited success.
The recent characterization of several broadly neutralizing
MAbs against the CD4-BS of Env revealed that the VH and VL
regions of these antibodies can be up to 50% divergent from the
corresponding germline sequences [7,37]. Xiao et al. reported that
the scFv form of the germline version of the broadly neutralizing
anti-CD4-BS antibody b12 does not bind clade B recombinant
Env proteins 89.6, Bal, JRFL and R2 [38,39]. Scheid et al.,
reported that the germline versions of certain broadly neutralizing
anti-CD4-BS MAbs fail to bind the Envs that were used to isolate
the mature version of these antibodies [7]. These observations
were made with a very limited number of recombinant Env
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proteins and thus far, the engagement of the germline BCR
versions of bNAbs by recombinant HIV Env immunogens has not
been examined in any great extent.
To compare the interactions of recombinant Env immunogens
with the germline and mature forms of bNAbs we focused on well-
characterized anti-HIV neutralizing antibodies whose epitopes are
located in the CD4-BS of Env; namely MAbs b12, NIH45-46 and
3BNC60. These MAbs were isolated from 3 different HIV-
infected subjects [5,7]. All three antibodies can neutralize a wide
range of primary viruses from distinct clades, although the breadth
and potency of NIH45-46 and 3BNC60 are far superior to those of
b12 [7,11]. Passive infusion studies conducted in non-human
primates with b12 have indicated that this antibody can protect
animals from experimental SHIV-infection [40].
The recombinant Envs used in our studies were derived from
diverse isolates from clades A, B and C (the three most
predominant clades worldwide [41,42]) and include constructs
that have been already tested in preclinical and clinical studies,
including the recent RV144 clinical trial [43]. We investigated the
interactions between soluble recombinant Env and the mature and
germline versions of these antibodies. We additionally sought to
characterize the relative contributions of the mature and germline
heavy and light chains to Env recognition, and to characterize how
affinity maturation at key residues within the b12 heavy chain
affects recognition of Env. Our results provide new insights into
the interaction between HIV Env immunogens and bNAbs to the
CD4-BS and provide alternative explanations as to why soluble
Env immunogens have so far failed to elicit broadly neutralizing
antibody responses.
Results
Mature and germline b12 VH and VL sequence
comparison
The b12 germline V, D and J genes were sequenced from the
subject from which b12 was isolated [44]. The gene usage of b12 is
VH1-03*01, D2-21*02 and J6*03 for VH, and KV3-20*01 and
KJ2*01 for VL. The VH and VL gene-usage for b12 differs from
that of several recently identified bNAbs that also target epitopes
within the CD4-BS of Env, such as VRC01, NIH45-46 or
3BNC60 [7,37]. The gene usage of these antibodies is VH1-2 for
all three, and KV3-11 for VRC01 and NIH45-46, and KV1D-33
for 3BNC60.
In the b12 mature heavy chain sequence, there are seven amino
acid residues flanking the predicted D gene segment; two (V95 and
G96) in the VD junction and five (S103, P104, Q105, D106 and
N107) in the DJ junction (Figure 1). Because it is not possible to
predict if the seven amino acid insertions took place during the VD
and DJ recombinations, or if they were introduced during B cell
affinity maturation, these seven amino acids were left unchanged
while constructing the b12 germline VH sequence used herein.
The actual b12 germline VH chain differs from the previously
published predicted b12 germline [39] at two positions: C99
(reported as S99 previously) and G101 (reported as D101
previously). The b12 mature and germline VH sequences differ
by 21% (24 amino acids) and the mature and germline VL
sequences differ by 19% (21 amino acids).
The mature NIH45-46 and 3BNC60 VH and VL regions have
acquired a higher number of somatic mutations (Figure S1). As a
result, NIH45-46 VH mature and germline sequences differ by
39% (44 amino acids), while the VL mature and germline
sequences differ by 25% (27 amino acids). The 3BNC60 germline
and mature VH sequences differ by 39% (46 amino acids), while
the VL mature and germline sequences differ by 30% (29 amino
acids).
The soluble germline version of IgG b12 does not bind
recombinant HIV-1 envelopes from a diverse panel of
viruses
Xiao et al. reported that the germline version of IgG b12 did not
interact with recombinant gp120 derived from the clade B viruses
Bal, JRFL, 89.6 and R2 [38]. Here we examined whether the
germline IgG b12 could interact with any of the recombinant Envs
in a large panel of Envs derived from clade A, B and C viruses
(Figure 2). These Envs included monomeric gp120 forms, as well
as monomeric and trimeric gp140 forms. Many of these proteins
have been previously evaluated as immunogens to elicit bNAbs in
pre-clinical and clinical studies.
By ELISA, mature IgG b12 bound to 39 of 56 Envs tested
(,69%). As expected, binding to the SF162-D368R gp120 or
SIVmac239 gp120, was not observed. The germline IgG b12 did
not display detectable binding to any of the envelopes tested,
irrespective of the clade of Env, whether it was in monomeric
gp120 or trimeric gp140 form, and whether the variable regions 1,
2 or 3 (SF162DV1, SF162DV2 and SF162DV3, respectively) were
present or not.
In parallel to the ELISA-based screening, we performed
Biolayer Interferometry (BLI) analysis to characterize in real-time,
any weak and transient interactions of the mature and germline
b12 with a subset (ten) of Envs (Figure 3). Mature b12 binding
was detectable to all of the Envs that showed detectable b12-
binding by ELISA (QH0692, 756c, 405c, 426c and 706c), as well
as two Envs that did not show ELISA binding, Q168a2 (orange)
and Q461e2 (green) (Figure 3A). In contrast, and in complete
agreement with the ELISA results, no interaction between the
germline b12 and any of the Envs tested was observed
(Figure 3B).
Both heavy and light chains of b12 are important for
binding to Env
The crystal structure of mature b12 in complex with the HIV-1
HxB2 gp120 core revealed that b12 binds Env exclusively through
its heavy chain [15]. Zwick et al. however reported that artificially
introduced mutations within the variable regions of the light chain
Author Summary
Recombinant HIV Envelope glycoproteins (Env), the sole
target of anti-HIV neutralizing antibodies, have, so far, not
been able to elicit broadly neutralizing antibodies (bNAbs)
although they express the corresponding epitopes. Such
constructs elicit neutralizing antibodies of very narrow
neutralizing breadth; antibodies whose epitopes are
primarily located within variable domains of Env. Diverse
approaches that have been evaluated over the past two
decades to overcome this limitation were met with limited
success. The exact reasons for the lack of elicitation of
bNAbs during immunization with Env are not well
understood. Here we show that recombinant Env proteins
are inefficient in engaging the predicted germline BCRs of
known bnAbs. Thus, our study provides new insights as to
why recombinant Env immunogens have failed to elicit
bNAbs. Our results indicate that, as a first step in eliciting
bNAbs by immunization, Env immunogens should be
designed that would engage the germline BCR versions of
bNAbs.
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of b12, can dramatically affect the binding of the mature IgG b12
to Env [45].
To investigate in more detail the relative contributions of the
heavy and light chains of b12 to its ability to recognize Env, we
produced recombinant b12 chimeric IgGs containing either the
germline heavy chain paired with the mature light chain (Chimera
1, gHC/mLC) or the mature heavy chain paired with the germline
light chain (Chimera 2, mHC/gLC) (Figure S2). We screened the
gHC/mLC and mHC/gLC IgG chimeras for binding by ELISA
and/or BLI to the panel of Envs listed in Figure 2 and Figure 3.
The gHC/mLC (Chimera 1) bound consistently to a single Env;
derived from the Clade B virus QH0692 (Figure 2 and
Figure 3C).
In contrast to the rare Env-reactivity displayed by the gHC/
mLC chimera, the mHC/gLC chimera (Chimera 2) displayed
detectable binding not only to QH0692, but also to three
additional clade B Envs (SF162, HXB2 and VC10042.Y22.E1A)
by ELISA (Figure 2 and Figure 4B). However, the mHC/gLC
chimera did not interact with any of the non-clade B Envs tested.
We note that the presence or absence of the first or second
hypervariable regions of gp120 (V1 and V2 loops respectively) did
not affect the recognition of the SF162 gp140 by chimera mHC/
gLC. Interestingly however, there was no detectable binding to the
SF162 Env once the V3 loop was deleted.
Collectively this analysis highlights the importance of the b12
heavy chain as the primary recognition determinant of diverse
Envs, but also shows that the light chain plays an important role in
the ability of b12 to recognize diverse Envs.
To further characterize the interactions of gHC/mLC and
mHC/gLC with QH0692 Env (which was the only Env from the
panel tested here that consistently bound to the mature and both
chimeric forms of b12), we performed binding kinetic analysis by
BLI (Figure 4A). The results from this analysis are summarized in
Table 1. The binding affinities (Ka) for both chimeras were lower
(by 2–3 Log10) than for the mature b12, which had an affinity of
2.0 nM for QH0692 gp120. The lower affinity of the gHC/mLC
compared to mature b12 is due to a 2 Log10 slower association rate
(ka). The mHC/gLC lower Ka compared to mature b12 is
primarily due to a faster dissociation rate (kd), although we note
that the ka of the mHC/gLC chimera is slower as well.
mHC/gLC but not gHC/mLC b12 IgG neutralizes certain
HIV-1 viruses
To determine whether the binding of b12 gHC/mLC and mHC/
gLC to certain soluble Envs translates into binding to the correspond-
ing virion-associated Env and leads to inhibition of viral infectivity, we
compared their abilities to bind Env fromQH0692, SF162 and HXB2
(Figure 4B) and to neutralize the corresponding virions (Figure 4C).
The gHC/mLC only bound QH0692 Env, while the mHC/gLC
bound all three Envs but with different affinities. Interestingly, while
mHC/gLC bound much less efficiently to QH0692 than gHC/mLC,
it bound with higher affinity to SF162 and HxB2 gp120s, while gHC/
mLC did not recognize these Envs.
Mature b12 IgG neutralized all three viruses, with IC50 values
of 0.22 mg/mL for QH0692, 0.01 mg/mL for SF162, and
0.002 mg/mL for HXB2. The mHC/gLC chimera did not
neutralize QH0692, but was able to neutralize HxB2 with an
IC50 value of 4.0 mg/mL and also neutralized SF162, but
significantly less potently. The observation that the neutralizing
potency of mHC/gLC against SF162 and HxB2 was reduced as
compared to the neutralizing potency of mature b12, further
supports the important role that that the light chain plays in the
binding and neutralizing activities of b12. The observed higher
neutralization potency of mHC/gLC against HXB2 than SF162 is
most likely due to the increased binding affinity of mHC/gLC to
HXB2 Env (Figure 4B).
Figure 1. Amino acid alignment of b12 mature and germline heavy and light chain variable regions. The framework (FR) and
complementary determining regions (CDR) are outlined, and the D- and J- gene segments are boxed. The complementarity determining (CDR) and
framework (FW) regions were determined using the IMGT/V-Quest tool (www.imgt.org). Amino acid numbering is based on the Kabat numbering
system. Seven amino acids (two in the VD joining region and five in the DJ joining region) that are present in the mature sequence (and which were
left unchanged in the germline sequence used here) are shown in oval. The four amino acids in the VH chain that are known to make direct contact
with the gp120 core are highlighted in yellow.
doi:10.1371/journal.ppat.1003106.g001
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Despite being able to bind the recombinant QH0692 Env,
gHC/mLC and mHC/gLC were unable to neutralize the
QH0692 virus, even at the highest concentration of mAb tested
(20 mg/mL). Potentially, this lack of neutralizing activity could be
due to a slower ka and/or faster kd of the two chimeric IgGs as
compared to those of the mature b12 (Figure 4A and Table 1).
Interaction of mature and germline versions of NIH45-46
and 3BNC60 with recombinant HIV Env
b12 was isolated by phage display [46,47] and the light chain
used to create the mature b12 form may not have been naturally
paired with the b12 heavy chain. Thus, the above described
results on the importance of the light chain of b12 in the
interaction of the mature and germline forms with Env can
simply be the result of improperly matched heavy and light
chains. To investigate whether the binding results discussed
above between Env and the mature/germline heavy/light chain
chimeric b12 IgGs, are specific to b12, we characterized the
relative contributions of mature and germline heavy and light
chains to Env binding for other CD4-BS antibodies. Recently,
several anti-CD4-BS antibodies with broad and potent neutral-
izing activities have been isolated from HIV-infected subjects
[7,9]. Since these antibodies were isolated from single sorted B
cells, the heavy and light chains are naturally occurring cognate
pairs. Two such antibodies are NIH45-46 and 3BNC60 [7,11].
We produced recombinant mature, germline, gHC/mLC and
mHC/gLC chimeric versions of NIH45-46 and 3BNC60 and
investigated their interactions with a panel of recombinant
gp120s from diverse genetic clades (Figure 5) using BLI .
Mature NIH45-46 bound to 23 of 24 HIV gp120s tested while
mature 3BNC60 bound to 19 of 20 HIV gp120s tested. Binding
of germline NIH45-46 or gHC/mLC NIH45-46 to any of the
Envs tested was undetectable. In contrast, the NIH 45-46 mHC/
gLC bound to 8 of the 24 Envs tested. The mature 3BNC60
bound to 23 of 25 Envs tested while mHC/gLC was able to bind
to a single Env tested, that from BAL. The gHC/mLC chimera
did not bind to any Envs tested.
Combined, our results indicate that both the heavy and light
chains of anti-CD4-BS bNAbs play important roles in Env
Figure 2. Binding of mature, germline and chimeric IgG b12 forms to the indicated recombinant Env was determined by ELISA as
described in the Materials and Methods section. (2): no binding; (+): binding; gp140(t): trimeric gp140; gp140(m): monomeric gp140.
doi:10.1371/journal.ppat.1003106.g002
Figure 3. Binding of mature, germline and mature/germline b12 chimeras to Env. Mature (A), germline (B), chimera 1 (C), or chimera 2 (D),
IgGs were immobilized to anti-human IgG FC capture BLI biosensors and Env proteins were in solution at 1.2 mM. The QH0692 and D368R Envs were
in gp120 form. The remaining Envs were in gp140 form (either as trimers or as monomers).
doi:10.1371/journal.ppat.1003106.g003
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binding, but that binding to some variants is maintained when
either the heavy or light chains are substituted for the
corresponding germline sequences.
Soluble Env trimers stimulate B-cell activation through
the mature but not through the germline b12 BCR
The above discussed binding experiments were performed with
soluble versions of the mature and germline b12 IgG. In the
context of B cell stimulation by an antigen however, the BCR is
anchored on the plasma membrane. Upon binding of antigen to
the cell surface-expressed BCRs and following BCR cross-linking,
specific intracellular activation signaling takes place. One conse-
quence of B cell activation is intracellular calcium mobilization. It
is possible that very weak interactions of BCRs with Env
immunogens can lead to B cell activation, even though these
interactions are either too weak to be determined biophysically, or
because these interactions are not taking place when the soluble
version of BCRs are used. To determine whether recombinant
Env can induce B-cell activation through the b12 BCR, we
monitored intracellular calcium mobilization of B cells expressing
Figure 4. Binding and neutralizing properties of the b12 mature, germline and mature/germline b12 chimeras to Env. (A) Kinetic
analysis of binding of mature b12 and of the two chimeras to QH0692 gp120. The Env concentrations tested are shown. A summary of the results is
presented in Table 1. (B) IgG-binding to QH0692, SF162 and HXB2 gp120s by ELISA. The shaded grey area indicates background (non-specific)
binding (determined as described in the Materials and Methods section). All binding curves are representative from two to four independent
experiments. (C) Neutralizing activities of IgG against QH0692, SF162 and HXB2 virions. Results are representative from two to four independent
experiments.
doi:10.1371/journal.ppat.1003106.g004
Table 1. Kinetic parameters of the mature and chimeric IgG
b12 forms for the QH0692 gp120.
b12 std error gHC/mLC std error mHC/gLC std error
Ka (M
21) 2.00E+09 3.16E+08 1.39E+07 3.20E+06 7.56E+06 1.37E+06
ka 7.87E+05 2.19E+05 7.76E+03 1.97E+03 4.85E+04 1.21E+04
kd 4.01E-04 4.14E-05 5.48E-04 1.28E-06 5.97E-03 5.31E-04
doi:10.1371/journal.ppat.1003106.t001
HIV Env-germline bNAb Interactions
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either the mature, germline, or the above discussed chimeric b12
BCRs in response to SF162 gp140 trimer and QH0692 gp140
trimer. All four BCRs were expressed on the cell surface at similar
levels (Figure 6A) and all four were functional as indicated by
Ca2+ flux when the BCRs were cross-linked on the surface of B
cells by anti-human IgG F(ab9)2 antibodies (Figure 6B).The
mature b12 bound to the SF162 gp140 trimers with greater
affinity than the mHC/gLC chimera, as observed with SF162
gp120 (Figure 4B), although the binding to trimeric gp140 was
more efficient than that for gp120 (compare Figure 4B with
Figure 6C). Very weak binding (detectable only at the highest
IgG concentrations used and not in every independent experi-
ment) was recorded with the gHC/mLC chimera while no binding
was detectable by the germline b12 (Figure 6C). The degree of
calcium mobilization upon addition of SF162 gp140 trimer
correlated with the strength of Env-IgG binding recorded by
ELISA. Robust Ca2+ flux was observed in response to mature b12
BCR engagement, an intermediate level of flux in response to
mHC/gLC BCR engagement, and no Ca2+ flux via the gHC/
mLC or germline BCRs (Figure 6D). These results are in
agreement with reports that the magnitude and duration of BCR
signaling is critically dependent on the affinity of the BCR-antigen
interaction [48].
The QH0692 gp140 trimer bound with high affinity to
mature b12 and to both chimeras (Figure 6E). We note that
the binding of gHC/mLC to the trimeric gp140 was far
superior to the binding to gp120 (compare Figure 4B with
Figure 6E). However, calcium mobilization was observed only
through the mature b12 BCR (Figure 6F). Potentially, the
orientation of the b12 epitope on the QH0692 gp140 trimers is
such that it is not conducive to BCR cross-linking on the B cell
surface.
Germline-to-mature mutations acquired during affinity
maturation confer increased Env-binding affinity and HIV
neutralization potency
Within the heavy chain of mature b12, four amino acids make up
40% of the direct contact surface with Env [15]. These four amino
acids are N31 (in CDRH1), P52 and Y53 (in CDRH2) and W100 (in
CDRH3) (highlighted in yellow in Figure 1). In the germline sequence
these four positions are occupied by different amino acids: S31, A52,
G53 andG100. These amino acid changes occurred therefore by AID-
mediated somatic hypermutation during affinity maturation of Env-
specific B cell clones in the subject from which b12 was isolated. To
better understand how germline-to-mature mutations in these four
positions affect the ability of b12 to recognize and neutralize diverse
viruses, we substituted the amino acids found in the germline sequence
to those found in the mature sequence. The mutations introduced
were: S31N, A52P and G53Y, G100W, and S31N/A52P/G53Y/
G100W (quadruple mutant). The germline heavy chain with these
mutations was co-expressed with either the mature light chain or the
germline light chains and the IgGs were tested for their binding and
neutralization properties (Figure 7).
When paired with the germline light chain, none of these
mutations conferred Env-binding or neutralization (data not
shown). When paired with the mature light chain, the effect of
these germline-to-mature mutations on Env-binding and HIV-
neutralization was Env and virus target-dependent. None of these
mutations conferred binding to SF162 Env (Figure 7A) or SF162
neutralization (Figure 7B). In the case of the SF162 Env therefore,
additional germline-to-mature mutations are required for binding
and neutralization. The quadruple mutant bound the HXB2 Env
and neutralized HXB2, albeit at a,46Log10 reduction compared
to mature b12. The S31N, A52P/G53Y, and G100W mutants
bound only to the QH0692 Env, as did the quadruple mutant.
Figure 5. Binding of mature, germline and chimeric IgG NIH45-46 and 3BNC60 to Env. Antibody binding to each Env was determined with
BLI using the antigen capture method as described in the Materials and Methods section. Symbols as in Figure 2.
doi:10.1371/journal.ppat.1003106.g005
HIV Env-germline bNAb Interactions
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Interestingly, binding of these variants to recombinant QH0692
Env did not result in QH0692 virus neutralization.
Discussion
The epitope of b12 is expressed on numerous recombinant Env-
derived immunogens that have been tested pre-clinically and
clinically for the elicitation of antibody responses similar to b12,
but there is no indication that b12-like neutralizing antibodies
have been elicited by such constructs. The reasons for the failure of
recombinant Env immunogens to elicit b12-like neutralizing
activities are not well understood. Understanding therefore how
b12 was generated in the context of natural infection is a critical
piece of information that is currently missing; information that
Figure 6. Env-specific B-cell activation through mature and chimeric b12 BCRs. (A) Cell-surface expression of b12 mature, germline and
chimeric BCRs on the surface of B cells. (B) Intracellular Ca2+ flux mediated by the mature, germline and chimeric BCRs following BCRs cross-linking by
goat anti-human IgG (H+L) F(ab9)2 in A20 cells. (C) Binding of mature, germline and chimeras to SF162 gp140 trimer. (D) Intracellular Ca2+ flux upon
addition of SF162 gp140 trimers to B cells (DG-75) expressing the indicated b12 BCRs. (E) Binding of mature, germline and chimeras to QH0692 gp140
trimer. (F) Intracellular Ca2+ flux upon addition of QH0692 gp140 trimers to B cells expressing the indicated b12 BCRs.
doi:10.1371/journal.ppat.1003106.g006
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would be very useful for the design of immunogens capable of
eliciting b12-like antibodies.
Our results indicate that the germline version of b12 is not
recognized by diverse Envs from clades A, B or C; Envs which are
recognized by the mature b12 antibody. Our results therefore
suggest that a potential reason why recombinant soluble Env
immunogens have failed so far to elicit b12-like antibody responses
may be the inability of these constructs to engage the germline
BCR versions of such antibodies. In the absence of such an
engagement, the process of B cell maturation that would lead to
the eventual production of b12-like antibody is unlikely to be
initiated.
The variable antibody regions of the mature and germline
sequences of b12 differ by 21% for the heavy chain and 19% for
the light chain and even more importantly, the four VH amino
acids of mature b12 that make direct contact with Env, differ
between the mature and germline sequences. When these four key
amino acids are mutated (individually or in combination) into
those present in the mature VH sequence (germline-to-mature
mutations) the germline heavy chain acquires Env-binding
abilities. However, the binding is dependent on the co-expression
of a mature variable light chain and is Env target dependent. In
fact, in certain cases, germline-to-mature conversion of all four key
positions in the VH chain does not lead to recognition of certain
Envs that are readily recognized by the fully matured antibody.
These observations suggest that the broad Env-recognition ability
of b12 necessitates a larger number of somatic mutations to take
place in the VH region during affinity maturation. Also, germline-
to-mature conversion of all four positions did not always lead to
HIV-neutralization even when they allowed Env-binding. There-
fore the broad neutralizing activity of b12 was acquired following
the introduction of multiple mutations in the germline VH region.
Some of these mutations may have allowed the maturing b12-like
antibody to bind Env without displaying its broad neutralizing
potential. Identifying the minimal number of germline-to-mature
mutations that are necessary for b12-like antibodies to display
cross-neutralizing activities will assist the design of immunogens
and immunization protocols that will lead to the minimum
maturation required of the germline b12 VH sequence to adopt its
broadly neutralizing form.
The critical role of the heavy chain of b12 for Env-binding is
highlighted by the fact that when the mature heavy chain is
substituted by the germline heavy chain (while the light chain is
kept in its mature form) only a single recombinant Env (out of 53
tested) was recognized. This Env, QH0692, is derived from a clade
B virus isolated during the first 3 months of infection from a
patient from Trinidad [49]. If only the heavy chain, and not the
light chain of b12 interacts with Env (as revealed by the crystal
structure of b12 bound to the HxB2 gp120 core [15], then it is
possible that the germline heavy chain of b12 binds the QH0692
Env. In this regard, the QH0692 Env is unique (for currently
unknown reasons) among all the recombinant Envs tested here.
The identification of a recombinant Env that is recognized by
the germline heavy chain of b12 supports the hypothesis that a
very small number of Envs are capable of engaging the germline
BCRs of b12-like antibodies. Also, this finding supports the
utilization of QH0692-derived constructs as future immunogens to
engage the fully germline version of the b12 BCR. Interestingly,
the QH0692 Env was not recognized by the gHC/mLC of the
other two anti-CD4-BS antibodies studied here. In fact the gHC/
mLC versions of NIH45-46 and of 3BNC60 did not recognize any
of the Envs tested. These observations suggest that a single Env
might not engage the germline BCR of these three antibodies.
From the point of view of immunogen design then, more than one
Env immunogen may need to be engineered to engage all three
germline BCRs tested here.
Reversion of the mature light chain to germline light chain
abrogates the ability of the antibody to bind the majority of Envs.
Thus, somatic mutations in the germline light chain are required
to take place for the most optimal orientation of the heavy chain
Figure 7. Effect of germline-to mature VH mutations on the binding and neutralizing activity of IgG b12 expressing the mature VL
chain. (A) The S31, A52P and G53Y, G100W, and S31N/A52P/G53Y/G100W amino acid mutations were introduced on the germline VH chain. The
mutated heavy chains were combined with the mature light chains and the corresponding IgGs were made. Their binding to the indicated
recombinant Envs was determined. The binding of the fully mature b12, that of the germline b12 and that of the gHC/mLC chimera were also
determined. The shaded grey area indicates background (non-specific) binding (determined as described in the Materials and Methods section). All
binding curves are representative from two to four independent experiments. (B) Neutralizing activities of the same IgGs against the indicated
virions.
doi:10.1371/journal.ppat.1003106.g007
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for Env-binding, or for stabilizing the interaction of the heavy
chain with Env. The optimal engagement of b12-like antibodies
with Env appears therefore to require multiple somatic mutations
to take place in both light and heavy chains. Similar observations
were made with two additional anti-CD4-BS antibodies, NIH45-
46 and 3BNC60. Overall our results support the hypothesis that
the pathway of affinity maturation which is required for the
binding of anti-CD4-BS antibodies to diverse HIV Envs depends
on somatic mutations introduced within both the heavy and light
chains of these antibodies. Our data also suggests that depending
on the Env target, the relative contribution of the heavy and light
chains to Env recognition will vary.
Our results also indicate that the ability to bind diverse Envs is
acquired gradually during affinity maturation, and is not inherent
in the germline versions of the antibodies studied here. Impor-
tantly, the above described results show that some Envs can bind
partial germline antibodies. Such Envs can serve as platforms to
design Env proteins capable of engaging the germline versions of
the antibodies examined here.
Although the above observations were made with the soluble
versions of the mature, germline and chimeric antibodies, they are
biologically relevant. The germline b12 BCR was unable to
mediate intracellular calcium mobilization (an indication of B cell
activation via BCR-antigen engagement). When the germline
heavy chain was combined with the mature light chain, Env-
mediated B cell activation was not observed. In contrast when the
mature heavy chain was combined with the germline light chain,
Env-specific B cell activation was observed, but at levels far
reduced as compared to those recorded when the mature heavy
and mature light chains were combined. Despite the fact that
trimeric QH0692 gp140 bound to both gHC/mLC and mHC/
gLC, it was not able to mediate calcium mobilization through
these two BCRs. This contrasts with the above-discussed
observation made with trimeric SF162 gp140, which bound the
mHC/gLC chimera and mediated calcium mobilization through
the corresponding BCR. At this stage we can only speculate that
the inability of the trimetric QH0692 gp140 to activate the mHC/
gLC BCR is related to inefficient BCR cross-linking on the surface
of B cells.
Although we examined diverse Envs from three different clades,
potentially a much larger screen of Envs is required to identify
those rare constructs that engage the germline BCRs of the type of
antibodies we examined here. For instance, it may be that the
development of such antibodies during natural HIV-1 infection
depends on the emergence of particular Env clones in certain
HIV-infected subjects; clones with particular structural character-
istics that allow them to engage the germline BCR form of bNAb
to the CD4-BS. In the context of HIV-1-infection, an alternative
possibility is that the maturation of bNAb precursors was initiated
in response to non-HIV antigens, and that the resultant
maturation antibody intermediates were capable of recognizing
bNAb epitopes on Env, as proposed for anti-gp41 antibodies [50].
We also note the possibility (not investigated here) that in the
context of infection, the germline BCRs of these antibodies are
initially engaged by membrane-anchored Env (for example, on the
virion surface or on the surface of infected cells).
As mentioned above it is not possible to predict the exact amino
acid composition of the VD and DJ joining regions in the true
germline versions of the antibodies examined here. Therefore, the
amino acids present in the mature antibodies in these two joining
regions were left unchanged. One could argue therefore that these
amino acids are not present in the ‘true’ germline BCRs of these
antibodies, and that in the absence of other mutations in V and J
regions, they play an inhibitory role in binding to certain
recombinant Envs. Finally, we note that the results presented
here were obtained with three NAbs whose epitopes are located
within the same region of Env; the CD4-BS. It remains to be
determined whether similar observations will be made with the
germline versions of NAbs that bind to epitopes outside the CD4-
BS. In this regard, it was reported that the germline versions of two
MAbs, CH01 and CH04, which bind complex quaternary
epitopes located outside the CD4-BS, can recognize certain
recombinant Envs [51]. Similarly, germline versions of the anti-
gp41 MAb 2F5 recognize certain forms of recombinant gp41 [52].
Overall our study provides new insights as to a potential reason
why recombinant Env immunogens have failed to elicit anti-CD4-
BS antibodies that display cross-neutralizing activities. Our results
indicate that, as a first step in eliciting broadly neutralizing anti-
CD4-BS antibodies by immunization, Env immunogens should be
designed that engage the germline BCR versions of broadly
neutralizing anti-CD4-BS antibodies.
Materials and Methods
Construction of plasmids expressing soluble b12 IgG
variants
To express soluble b12 IgG variants, two separate pTT5-based
vectors containing the b12 heavy and light chain variable and
constant region open reading frames were used (provided by Dr.
Pamela Bjorkman, California Institute of Technology, Pasadena,
CA). The b12 heavy and light chain germline variable sequences
from the original donor from which b12 was isolated [44] were
used to replace the mature b12 variable regions in the pTT5
vectors using an EcoRI-NotI strategy for the heavy chain and
EcoRI-EcoRI for the light chain.
Point mutations in the b12 germline heavy chain sequences
were introduced using oligonucleotide mediated site directed
mutagenesis (Stratagene Quick Change II system from Agilent
Technologies, Santa Clara, California). For constructs bearing
multiple point mutations, sequential rounds of site-directed
mutagenesis were performed, with the exception of the residues
at position 52 and 53 in the heavy chain, which were mutated in
combination with a single set of mutagenic primers. Oligonucle-
otide primers used in this study are listed in Table S1.
Mature/germline heavy and light chain b12 chimeras were
generated by co-expressing the plasmid encoding the germline
heavy chain with the plasmid encoding the mature light chain
(Chimera 1, also referred to as gHC/mLC), or by co-expressing
the plasmid encoding for the mature heavy chain with the plasmid
encoding the germline light chain (Chimera 2, also referred to as
mHC/gLC). The germline sequences of NIH45-46 and 3BNC60
were previously reported [7].
Plasmids expressing additional IgGs
Plasmids expressing the heavy and light chains of the mature
and germline versions of NIH45-46 and 3BNC60 were kindly
provided by Michel Nussenzweig (The Rockefeller University).
Expression and purification of IgG
IgGs were produced by transient transfection of HEK 293e cells
suspension cells, as previously described [53,54] with a few
modifications. Briefly, cells were suspended in FreeStyle 293
expression medium (Invitrogen, Carlsbad, CA) to a density of 20
million cells/mL. Heavy and light chain expressing pTT5 vectors
were added to a final concentration of 6 mg/mL of each,
immediately followed by the addition of linear PEI MAX
(Polysciences Inc, Warrington, PA) to a final concentration of
24 mg/mL for 3 hours at 37uC. At this point the cell density was
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reduced to 1 million cells per mL in ExCell Vpro medium
supplemented with 20 mM HEPES and 4 mM GlutaMax.
Culture supernatants were harvested after 5 days and filtered
through a 0.2 mM Millipore filter. Supernatants were diluted 1:1
with PBS pH 7.4 and loaded on protein-A sepharose resin (GE
healthcare) via gravity flow. IgG was eluted from the column using
0.1 M citrate, pH 2.5 into 1/10 volume of 1 M Tris pH 9.0.The
purified IgG sample was buffer exchanged using 40 KDa MW
cutoff Zeba desalting columns (Thermo Scientific). IgGs were
quantitated by A280 and purity was verified by SDS-PAGE. IgG
samples were aliquoted and stored at 220uC until use.
Construction of BCR versions of b12 antibodies
To generate plasmids expressing the membrane-anchored
version of the b12 IgGs (that is, with the transmembrane and
cytoplasmic regions of human IgG1) the following strategy was
used. The U-b12 plasmid [55] (provided by David Baltimore,
CalTech) was used for these studies. The U-b12 plasmid expresses
the mature heavy and light b12 IgG chains as a single polypeptide
separated by a furin cleavage site and an F2A peptide sequence.
Those regions were PCR amplified and replaced the b12 heavy
chain insert in the pTT5-b12HC vector using the EcorI and NotI
sites. Thus, a pTT5 plasmid was generated that expresses both the
heavy and light mature chains of IgG b12. The constant IgG splice
variant cDNA (containing the two exons which encode the
transmembrane and cytoplamic domains of human IgG) was
synthesized by Genscript (Piscataway, NJ). That sequence replaced
the soluble IgG heavy chain, the above pTT5 vector. The new
vector, pTT5-mb12-BCR, expresses the membrane-anchored
version of mature b12. The germline and the mature/germline
chimeras were generated by replacing the mature b12 sequences
by the appropriate germline VH and VL sequences.
Recombinant HIV Envelope gp120 and gp140 proteins
Envelope proteins used in this study are listed in Figure 2. All
recombinant gp120 proteins used in this study were obtained
commercially (Immune Technologies, New York, New York), with
the exception of SF162 gp120 which was produced in-house.
D368R gp120 is derived from the SF162 gp120 by introducing an
aspartic acid at position 368 within the CD4-BS. This mutation is
known to abrogate the binding of CD4 to gp120, as well as the
binding of most anti-CD4-BS antibodies [56,57]. The Clade A:
Q168a2, Q259d2, Q461e2, Q769h5; Clade B: SF162, SF162DV1,
SF162DV2, SF162DV3, VC10042.05, VC10042.Y22.05.rm,
VC10042.Y22.08 and VC10042.Y22.E1A; and Clade C: 140c,
327c, 405c, 426c, 459c, 706c, 756c, and 823c monomeric and/or
trimeric gp140 proteins were expressed in mammalian cells and
purified as we previously described by [17,53,54]. Clade B Envs
JRCSF, SF162, ADA, JRFL, YU2 and HXBc2 were derived from
viruses isolated during chronic infection. Clade C Envs Du151,
Du422, CAP45, ZM249, ZM109F, ZM197M, ZM53M, ZM233M
and Clade B Envs QH0692, AC10.0, PVO, TRO, RHPA, TRJO,
WITO, REJO, THRO were derived from viruses isolated during
the first 6 months of infection [10,49,58]. Clade A Envs Q168a2,
Q259d2, Q461e2 and Q769h5 were derived from viruses isolated
between 28 and 75 days post-infection [59] . The clade B Envs G4,
C6a, F8, H5a and C4a were derived from a single HIV+ subject
and isolated from 1–4 years post-infection. Clone G4 was isolated at
year 1, F8 at 1.5 years, C6a at year 2, H5a at year 3.5 and C4a at 4
years post-infection (D. Malherbe et al, unpublished data). The
clade C Envs 140c, 327c, 405c, 426c, 459c, 706c, 756c, and 823c
were obtained during the first 3 months of infection from
participants of the HVTN 503 clinical trial who became infected.
Envs VC10042.05, VC10042.Y22.E1A, VC10042.Y22.08,
VC10042.Y22.05.rm were derived from virus circulating in an
elite neutralizer (VC10042) [3] at 22 years post-infection (DN
Sather, submitted manuscript). All ‘in house’ produced Envs were
expressed and purified as previously described [54,60].
ELISA
HIV gp120 and gp140 proteins were adsorbed onto 96-well
Immulon 2HB-coated microtiter ELISA plates overnight at room
temperature at a concentration of 0.5 mg/mL in 0.1 M NaHCO3
pH 9.5. Wells were washed 4 times in PBS + 0.02% Tween 20
(wash buffer) prior to blocking at 37uC for 2 hours with 300 mL
per well of PBS containing 8% milk and 2% BSA. Plates were
washed four times with wash buffer prior to addition of anti-Env
MAbs in dilution buffer (PBS 8% milk 2% BSA 0.03% Tween 20).
MAbs were added at a concentration of 30 mg/mL and three-fold
serial titrations were performed (in duplicate), followed by a
1 hour incubation at 37uC. Wells were washed 4 times (PBS +
0.02% Tween 20) and HRP-conjugated goat anti-human IgG
(Southern BioTech, Birmingham, Alabama) was added at a
1:3000 dilution in dilution buffer for 1 hour at 37uC. At that point,
the wells were washed 4 times with wash buffer and 50 mL of Ultra
TMB substrate (Thermo Scientific/Pierce, Rockford Illinois) was
added for three minutes at which point 50 mL of 1 N H2SO4 were
added per well. The A450 of each well was read on a Versamax
plate reader, and the analysis was performed using the Prism 5
package (Graphpad Software). Each experiment was indepen-
dently replicated two to four times. The background absorbance
(due to minimal non-specific binding of MAbs to wells) was
calculated by taking the mean plus the standard deviation of the
background absorbances against SF162 D368R gp120 of all MAbs
tested. That value was determined to be equal to an A450 of
0.16 nm.
Biolayer interferometry analysis of MAb-Env binding
The Octet KQe instrument (ForteBio, Inc, Menlo Park, CA)
was used to perform biolayer interferometry (BLI) to detect the
interaction of MAbs with soluble recombinant Env proteins.
(a) Antibody-capture method: Mature, germline and mature/
germline chimeric b12 IgGs (at 15 mg/mL in PBS) were
immobilized onto anti-human IgG FC capture (AHC) biosensors
(Fortebio). The biosensors were then immersed into wells of a 96
well plate containing Env proteins at 1.02 mM concentration in 16
kinetics buffer (16 PBS, 0.01% BSA, 0.02%, Tween 20, and
0.005% NaN3) (association phase). The biosensors were subse-
quently immersed into wells containing only buffer (dissociation
phase). Biosensors were regenerated using 0.1 M glycine (pH 1.7)
followed by neutralization in buffer and reloading of IgG. The
following method program was used for each sample tested: 1)
Baseline measurement for 180 sec, 2) IgG loading for 300 sec, 3)
Baseline measurement for 180 sec, 4) Association phase for
300 sec, 5) Dissociation phase for 600 sec. These steps were
followed by regeneration for 15 sec and neutralization for 15 sec,
repeated for 3 cycles.
(b): Antigen-capture method: Recombinant His-tagged antigens
(at 20 mg/mL in PBS) (Immune Technologies were immobilized
onto Ni-NTA biosensors (Fortebio). The biosensors were then
immersed into wells of a 96 well plate containing mature, germline
and mature/germline chimeric NIH45-46 and 3BNC60 IgGs at
100 nM concentration in 16 kinetics buffer (association phase).
The biosensors were subsequently immersed into wells containing
only buffer (dissociation phase). Biosensors were regenerated using
three cycles of treatment with 0.1 M glycine (pH 1.7) followed by
neutralization in 16 kinetics buffer followed by a treatment with
10 mM NiCl2. The following method program was used for each
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sample tested: 1) Baseline measurement for 300 sec, 2) Env
loading for 300 sec, 3) Baseline measurement for 60 sec, 4)
Association phase for 1200 sec, 5) Dissociation phase for 1200 sec.
These steps were followed by regeneration for 15 sec and
neutralization for 15 sec, repeated for 3 cycles and a final
recharge step for 60 sec. Negative binding using the antigen
capture method was defined as having a less than 0.2 nM shift.
Ka, ka and kd determination was performed by antibody-capture
BLI using 2-fold serial dilutions of recombinant Env over a range
of concentrations roughly 10-fold below and 10-fold above the
approximate Ka for each mAb tested. The reported Ka, ka and kd
values were determined by taking the mean of the Ka, ka and kd
values from all binding curves that matched the theoretical fit with
an R2 value of $0.95.
Viral neutralization assays
To test the neutralization potency of b12 IgG variants,
inhibition of viral entry in luciferase reporter cells lines was
performed as described previously [2,3,26,61]. For CCR5-tropic
viruses, the TZM-bl cell line was used as target, and for CXCR4-
tropic viruses, the NIH-U87 cell line expressing CD4 and the
CXCR4 co-receptor was used as target. The cells were maintained
in DMEM, (Dubelco’s Modified Eagle’s Medium, Cellgrow)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin. TZM-bl cells
were plated at a density of 56104 cells per well and U87 cells at a
density of 76104 per well 24 hours prior to addition of virus and
antibody. Antibodies serially diluted in microtiter wells starting at
a concentration of 20 mg/mL and a total volume of 30 mL per
well. 30 mL of virus (previously determined to result in 16105
luciferase units was added to each well containing the titrated
antibodies. Antibody-virus mixtures in duplicate wells were
incubated at 37uC for 1.5 hours. During the last 30 minutes of
the incubation, cells were treated at 37uC with 2 mg/mL of
polybrene. The polybrene was then aspirated from the cells and
replaced with 50 mL of antibody-pseudovirus mixture. Plates were
incubated at 37uC for 72 hours, media was aspirated and cells
were lysed to measure luciferase activity using Steady-Glo
Luciferase Reagent (Promega, Madison, Wisconsin). The percent
neutralization at each MAb concentration was determined as
previously described [17,61].
B cell lines
The A20 mouse B cell lymphoma (ATCC # TIB-208) and the
DG-75 human Burkitt’s lymphoma (ATCC # CRL-2625) cell
lines were used for these assays. A20 cells were maintained in
RPMI-1640 supplemented with 10% FBS and 0.05 mM b-
mercaptoethanol and the DG-75 cells were maintained in RPMI-
1640 supplemented with 10% FBS. DG-75 cells express human
IgM on their surface, while A20 cells express mouse IgG on their
surface.
Transfection of B cell lines with exogenous BCRs
Both A20 and DG-75 B cell lines were used for the cell surface
expression of human IgG BCRs. 26106 cells were re-suspended in
100 ml of cell line nucleofector solution V (Lonza, Cologne
Germany) containing 5 mg of the appropriate pTT5-BCR
plasmid. Transfections of A20 and DG-75 cells were performed
using Amaxa Nucleofector II, programs L-013 and O-006,
respectively (Lonza, Cologne Germany). Surface staining of
exogenous human BCRs was performed using allophycocyanin
(APC) conjugated mouse monoclonal anti-human IgG (BD
Pharmingen Cat# 550931) at a 1/10 dilution. Exogenous human
BCR cross-linking on the surface of B cells was achieved with the
use of the goat anti-human IgG F(ab9)2 fragment (20 mg/ml;
Jackson Immunoresearch Cat. # 309-005-006).
Analysis of intracellular calcium mobilization
24 h post-transfection with plasmids expressing human BCRs,
A20 or DG-75 cells were loaded with Fluo-4 Direct calcium
indicator (Invitrogen, Carlsbad CA) in RPMI-1640 medium
containing 10% FBS at 37uC for 1 h. The cells were then washed
twice with 5 ml in RPMI-1640 containing 10% FBS, resuspended
at ,1 million cells/ml in RPMI-1640 and subjected to analysis of
calcium flux at a medium flow rate on an LSR II cytometer
(Beckton Dickinson).
(a) Defining the functionalities of the exogenous BCRs:
Minimum levels of background fluorescence (MinFL) were
determined by averaging the background Fluo-4 fluoresence in
cells for 30 s. After determining MinFL, exogenous BCR cross-
linking on the surface of transfected cells was performed in mouse
A20 cells by the addition of goat anti-human IgG (H+L) F(ab9)2 to
a concentration of 20 mg/ml. Cell-associated changes in Fluo-4
fluorescence were further monitored for 210 seconds. At that time,
ionomycin was added to a final concentration of 6.5 nM for 60 s.
Maximum Fluo-4 fluorescence (MaxFL) recorded following the
addition of ionomycin was determined by averaging changes in
Fluo-4 fluorescence recorded between 290 s and 300 s.
(b) Recombinant soluble Env-mediated BCR activation: The
ability of recombinant soluble Env proteins to stimulate calcium
flux in DG-75 cells expressing the exogenous BCRs. Once the
MinFL was determined as discussed above, soluble recombinant
Env proteins were added to a final concentration of 30 mg/ml.
Changes in Fluo-4 fluorescence associated with cells expressing the
exogenous BCRs (APC positive cells) were further monitored for
210 seconds, at which point ionomycin was added and the MaxFL
was determined.
For both (a) and (b) the percent of maximum Fluo-4
fluorescence at each time point t was determined using the
formula: (Fluorescence at t-MinFL)/(MaxFL-MinFL)6100. This
analysis was performed on both the BCR positive (anti-IgG-APC
positive) and BCR negative cells (anti-IgG-APC negative) simul-
taneously. The background Fluo-4 fluorescence signal from the
BCR negative cells was subtracted from that of the BCR positive
population at each time point.
Supporting Information
Figure S1 Amino acid alignment of b12 mature and
germline heavy and light chain variable regions for NIH
46-46 (A) and 3BNC60 (B). The framework (FR) and
complementary determining regions (CDR) are outlined, and the
D- and J- gene segments are boxed. The complementarity
determining (CDR) and framework (FW) regions were determined
using the IMGT/V-Quest tool (www.imgt.org). Amino acid
numbering is based on the Kabat numbering system.
(TIF)
Figure S2 Schematic representation of mature, germ-
line and chimeric b12 antibodies.
(TIF)
Table S1 Oligonucleotides used in this study.
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